Atlas Trials

A Multicenter, Prospective Study of Diarrhea Tolerance of Pyrotinib Combined With Trastumab and Taxane in the First-line Treatment of HER2-positive Advanced Breast Cancer

Clinical trial NCT06362096 · UNKNOWN

Trial details

NCT number
NCT06362096
Sponsor
Huihua Xiong
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Breast Cancer
Start date
2024-05-01
Primary completion
2025-05-01
Enrollment
72

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.